title: 5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?
abstract: Prostate cancer (PCa) is a slow, progressive disease. Prostate specific antigen testing, screening, and aggressive case identification has made PCa the most frequently diagnosed cancer. Concerns regarding overdiagnosis and overtreatment flourish on a large scale. In order to avoid overtreatment for those in whom therapeutic intervention is not required, active surveillance for eligible patients with the use of 5-alpha reductase can be considered a safe and a promising approach to delay the progression of the disease with minimal side effects.
authors.affiliation: Division of Urology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada. Ghazi.aledwan@uhn.ca
authors.forename: Ghazi
authors.initials: G
authors.lastname: Al Edwan
authors.forename: Neil
authors.initials: N
authors.lastname: Fleshner
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D001378:Azasteroids / Q000627:therapeutic use*; D018450:Disease Progression; D000068538:Dutasteride; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D007610:Kallikreins / Q000097:blood; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D018570:Risk Assessment; D057832:Watchful Waiting / Q000379:methods*
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D018120:Finasteride; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen; D000068538:Dutasteride